These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1023 related articles for article (PubMed ID: 31543674)

  • 1. Role of NLRP3 inflammasome in inflammatory bowel diseases.
    Tourkochristou E; Aggeletopoulou I; Konstantakis C; Triantos C
    World J Gastroenterol; 2019 Sep; 25(33):4796-4804. PubMed ID: 31543674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NLRP3 Inflammasome: Checkpoint Connecting Innate and Adaptive Immunity in Autoimmune Diseases.
    Zhang Y; Yang W; Li W; Zhao Y
    Front Immunol; 2021; 12():732933. PubMed ID: 34707607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of NLRP3 inflammasome in infection-related, immune-mediated and autoimmune skin diseases.
    Wang D; Duncan B; Li X; Shi J
    J Dermatol Sci; 2020 Jun; 98(3):146-151. PubMed ID: 32173167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production.
    Yu X; Lan P; Hou X; Han Q; Lu N; Li T; Jiao C; Zhang J; Zhang C; Tian Z
    J Hepatol; 2017 Apr; 66(4):693-702. PubMed ID: 28027970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors.
    Bauer C; Duewell P; Lehr HA; Endres S; Schnurr M
    Dig Dis; 2012; 30 Suppl 1():82-90. PubMed ID: 23075874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorofenidone attenuates interleukin-1β production by interacting with NLRP3 inflammasome in unilateral ureteral obstruction.
    Zheng L; Zhang J; Yuan X; Tang J; Qiu S; Peng Z; Yuan Q; Xie Y; Mei W; Tang Y; Meng J; Hu G; Tao L
    Nephrology (Carlton); 2018 Jun; 23(6):573-584. PubMed ID: 28437591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms regulating NLRP3 inflammasome activation.
    Jo EK; Kim JK; Shin DM; Sasakawa C
    Cell Mol Immunol; 2016 Mar; 13(2):148-59. PubMed ID: 26549800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NLRP3 Inflammasome and Inflammatory Bowel Disease.
    Zhen Y; Zhang H
    Front Immunol; 2019; 10():276. PubMed ID: 30873162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of adaptive immunity by the NLRP3 inflammasome.
    Chen M; Wang H; Chen W; Meng G
    Int Immunopharmacol; 2011 May; 11(5):549-54. PubMed ID: 21118671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of carboxyamidotriazole on 2,4,6-trinitrobenzene sulfonic acid-induced colitis model is associated with the inhibition of NLRP3 inflammasome and NF-κB activation.
    Du X; Chen W; Wang Y; Chen C; Guo L; Ju R; Li J; Zhang D; Zhu L; Ye C
    Int Immunopharmacol; 2017 Apr; 45():16-25. PubMed ID: 28152446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases.
    Jahan S; Kumar D; Chaturvedi S; Rashid M; Wahajuddin M; Khan YA; Goyal SN; Patil CR; Mohanraj R; Subramanya S; Ojha S
    Curr Med Chem; 2017; 24(16):1645-1670. PubMed ID: 28245768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease.
    Perera AP; Kunde D; Eri R
    Curr Pharm Des; 2017; 23(16):2321-2327. PubMed ID: 28155620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis.
    Gong Z; Zhou J; Zhao S; Tian C; Wang P; Xu C; Chen Y; Cai W; Wu J
    Oncotarget; 2016 Dec; 7(51):83951-83963. PubMed ID: 27924062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases.
    Mulay SR
    Kidney Int; 2019 Jul; 96(1):58-66. PubMed ID: 30922667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-coding RNAs: The key regulators in NLRP3 inflammasome-mediated inflammatory diseases.
    Feng X; Luo D; Wei G; Zhan F; Hua F; Xu G
    Int Immunopharmacol; 2021 Nov; 100():108105. PubMed ID: 34481143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sendai Virus V Protein Inhibits the Secretion of Interleukin-1β by Preventing NLRP3 Inflammasome Assembly.
    Komatsu T; Tanaka Y; Kitagawa Y; Koide N; Naiki Y; Morita N; Gotoh B; Yokochi T
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammasome Regulation: Therapeutic Potential for Inflammatory Bowel Disease.
    Xu Q; Zhou X; Strober W; Mao L
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33808793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NLRP3 inflammasome in kidney disease and autoimmunity.
    Hutton HL; Ooi JD; Holdsworth SR; Kitching AR
    Nephrology (Carlton); 2016 Sep; 21(9):736-44. PubMed ID: 27011059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The strategies of targeting the NLRP3 inflammasome to treat inflammatory diseases.
    Jiang H; Gong T; Zhou R
    Adv Immunol; 2020; 145():55-93. PubMed ID: 32081200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimethyl sulfoxide inhibits NLRP3 inflammasome activation.
    Ahn H; Kim J; Jeung EB; Lee GS
    Immunobiology; 2014 Apr; 219(4):315-22. PubMed ID: 24380723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.